Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.

Heikkinen T, Korpela T, Fagerholm R, Khan S, Aittomäki K, Heikkilä P, Blomqvist C, Carpén O, Nevanlinna H.

Breast Cancer Res Treat. 2013 Aug;141(1):79-88. doi: 10.1007/s10549-013-2671-2. Epub 2013 Aug 24.

PMID:
23974830
2.

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.

3.

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.

Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S; West German Study Group.

Ann Oncol. 2008 May;19(5):861-70. doi: 10.1093/annonc/mdm551. Epub 2008 Jan 3.

4.
5.

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.

Abdel-Fatah TM, McArdle SE, Johnson C, Moseley PM, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Br J Cancer. 2014 May 13;110(10):2450-61. doi: 10.1038/bjc.2014.168. Epub 2014 Apr 22.

6.

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.

Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ.

J Clin Oncol. 2008 Nov 1;26(31):5027-35. doi: 10.1200/JCO.2007.14.6597. Epub 2008 Sep 2.

7.
8.

LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.

Ahn SG, Dong SM, Oshima A, Kim WH, Lee HM, Lee SA, Kwon SH, Lee JH, Lee JM, Jeong J, Lee HD, Green JE.

Breast Cancer Res Treat. 2013 Aug;141(1):89-99. doi: 10.1007/s10549-013-2662-3. Epub 2013 Aug 10.

PMID:
23933800
9.

Integrated gene expression profile predicts prognosis of breast cancer patients.

Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, Shao ZM.

Breast Cancer Res Treat. 2009 Jan;113(2):231-7. doi: 10.1007/s10549-008-9925-4. Epub 2008 Feb 16.

PMID:
18278552
10.

Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.

Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH Jr.

Clin Cancer Res. 2011 May 1;17(9):2874-84. doi: 10.1158/1078-0432.CCR-10-2334. Epub 2011 Mar 17. Erratum in: Clin Cancer Res. 2011 Nov 1;17(21):6952. Retrouvay, Hélène [corrected to Retrouvey, Hélène].

11.

Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.

Flowers A, Chu QD, Panu L, Meschonat C, Caldito G, Lowery-Nordberg M, Li BD.

Surgery. 2009 Aug;146(2):220-6. doi: 10.1016/j.surg.2009.05.010.

PMID:
19628077
12.

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.

Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP.

Breast Cancer Res Treat. 2010 Nov;124(2):387-91. doi: 10.1007/s10549-010-1142-2. Epub 2010 Sep 8.

PMID:
20824324
13.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
14.
15.

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G.

Breast Cancer Res. 2009;11(5):R69. doi: 10.1186/bcr2363. Epub .

16.

Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).

Holm NT, Abreo F, Johnson LW, Li BD, Chu QD.

Breast Cancer Res Treat. 2009 Jan;113(2):293-9. doi: 10.1007/s10549-008-9921-8. Epub 2008 Feb 13.

PMID:
18270814
17.

Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.

Inamdar KV, Romaguera JE, Drakos E, Knoblock RJ, Garcia M, Leventaki V, Medeiros LJ, Rassidakis GZ.

Cancer. 2009 Oct 15;115(20):4727-36. doi: 10.1002/cncr.24506.

18.

Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.

von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C.

J Clin Oncol. 2011 Jun 1;29(16):2150-7. doi: 10.1200/JCO.2010.31.9079. Epub 2011 Apr 25.

19.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

20.

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.

Breast Cancer Res. 2008;10(5):R86. doi: 10.1186/bcr2156. Epub 2008 Oct 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk